Objectives & Accreditation
Leading scientists will discuss new targets and drugs for the treatment of Alzheimer’s disease and novel approaches to current therapy.
Objectives and Expected Results
- Evaluate current therapies for AD, their side effects, and their benefits for daily living of the patient.
- Describe new methods of diagnosing AD by using imaging and biomarkers.
- Discuss various pharmacological interventions designed to attenuate disease progression.
- State safety monitoring needed for pharmacological interventions.
- Evaluate failures and errors in the attempts to develop new treatments for AD.
- Discuss latest results of clinical trials of new drugs and treatments.
An oral communication session will be open to young scientists.
Neurologists, psychiatrists, geriatricians and pharmacologists.
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Southern Illinois University School of Medicine, the University of Geneva and the Geneva University Hospitals. The Southern Illinois University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Southern Illinois University School of Medicine designates this live activity for a maximum of 20 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Industry-sponsored sessions are not designated for AMA PRA Category 1 Credit™.